Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
15/03/202117:00PR Newswire (US)Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall ...NASDAQ:REGNRegeneron Pharmaceuticals Inc
04/03/202122:26Dow Jones NewsRegeneron, Sanofi: FDA to Review Dupixent for Asthma Attacks in ChildrenNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/03/202116:59PR Newswire (US)FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe AsthmaNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/202118:52TipRanksRegeneron Antibody Therapy For Cat-Allergic Asthma Patients Shows Positive ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
28/02/202110:25PR Newswire (US)Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild AsthmaNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/02/202100:05Dow Jones NewsEuropean Medicines Agency Supports Roche's Covid-19 Antibody CocktailNASDAQ:REGNRegeneron Pharmaceuticals Inc
26/02/202122:46PR Newswire (US)EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 PatientsNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/02/202123:00PR Newswire (US)Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 ...NASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202105:45Dow Jones NewsRegeneron, Sanofi Gets FDA OK of Libtayo in Advanced Non-Small Cell Lung CancerNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202105:00PR Newswire (US)FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD...NASDAQ:REGNRegeneron Pharmaceuticals Inc
17/02/202105:01Edgar (US Regulatory)Schedule 13gNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/02/202108:15PR Newswire (US)Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202119:50TipRanksRegeneron Wins FDA Nod For Evkeeza Antibody Therapy; Street Sees 34% UpsideNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202117:00PR Newswire (US)The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-s...NASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202109:04PR Newswire (US)U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent LitigationNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202107:01Dow Jones NewsRegeneron: FDA Approves Evkeeza in Rare Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
12/02/202106:00PR Newswire (US)FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
10/02/202109:22PR Newswire (US)FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell CarcinomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
09/02/202102:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/02/202101:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202123:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202123:16Dow Jones NewsRegeneron's Eylea, Covid-19 Treatment Contribute to 4Q Sales GainsNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202122:30PR Newswire (US)Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
03/02/202108:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202101:59PR Newswire (US)New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAA...NASDAQ:REGNRegeneron Pharmaceuticals Inc
28/01/202108:07Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
28/01/202100:05Dow Jones NewsRegeneron: REGEN-COV Is Active Against U.K., South Africa SARS-CoV-2 VariantsNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/01/202123:00PR Newswire (US)REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South AfricaNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/01/202103:19Dow Jones NewsRegeneron Antibody Drug Temporarily Protects Against Covid-19, Preliminary Data ShowNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/01/202100:18Dow Jones NewsRegeneron: Interim Data Positive With REGEN-COV as Passive Vaccine to Prevent Covid-19NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN